DeepMed Research

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers

Recruiting

Conditions: Healthy

First Posted Date: 2023-11-07

Last Posted Date: 2024-12-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 120

Registration Number: NCT06120244

Locations: 🇺🇸
Rocky Mountain Laboratories, Hamilton, Montana, United States

A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

Phase 1

Recruiting

Conditions: Congenital Cytomegalovirus Infection

Interventions: Drug: Letermovir

First Posted Date: 2023-11-07

Last Posted Date: 2025-05-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 12

Registration Number: NCT06118515

Locations: 🇺🇸
Nationwide Children's Hospital-Neonatology-Center for Perinatal Research, Columbus, Ohio, United States
🇺🇸
Children's of Alabama Child Health Research Unit (CHRU), Birmingham, Alabama, United States
🇺🇸
Children's National Medical Center - Sheikh Zayed Campus - Infectious Disease, Washington, District of Columbia, United States

and more 7 locations

Cardamom and Topical Roseomonas in Atopic Dermatitis

Phase 2

Recruiting

Conditions: Atopic Dermatitis
Eczema

Interventions: Drug: Placebo (sucrose)
Drug: Roseomonas mucosa (RSM2015) and Cardamom seeds

First Posted Date: 2023-10-24

Last Posted Date: 2025-03-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 240

Registration Number: NCT06096857

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates

Phase 2

Recruiting

Conditions: Liver Transplant

Interventions: Drug: CMV-MVA Triplex
Drug: Placebo for CMV-MVA Triplex

First Posted Date: 2023-10-10

Last Posted Date: 2025-04-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 416

Registration Number: NCT06075745

Locations: 🇺🇸
University of Alabama at Birmingham, School of Medicine, Birmingham, Alabama, United States
🇺🇸
University of California, San Diego School of Medicine, La Jolla, California, United States
🇺🇸
Stanford University, Redwood City, California, United States

and more 15 locations

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Phase 1

Suspended

Conditions: HIV-1-infection

Interventions: Biological: Placebo
Biological: ChAdOx1.tHIVconsv1
Biological: ChAdOx1.HIVconsv62
Biological: MVA.tHIVconsv3
Biological: MVA.tHIVconsv4
Drug: Vesatolimod (VES)
Drug: GS-5423
Drug: GS-2872

First Posted Date: 2023-10-06

Last Posted Date: 2025-04-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 45

Registration Number: NCT06071767

Locations: 🇧🇷
Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS, Porto Alegre, Rio Grande Do Sul, Brazil
🇺🇸
University of California, San Diego AntiViral Research Center CRS, San Diego, California, United States
🇺🇸
Ponce de Leon Center CRS, Atlanta, Georgia, United States

and more 11 locations

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

Phase 1

Recruiting

Conditions: End Stage Renal Failure on Dialysis
Kidney Failure
Kidney Transplant

Interventions: Drug: Cyclophosphamide
Biological: CART-BCMA
Biological: huCART19
Drug: Fludarabine

First Posted Date: 2023-09-28

Last Posted Date: 2025-01-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT06056102

Locations: 🇺🇸
NYU Langone Health (Site #: 71177), New York, New York, United States
🇺🇸
Massachusetts General Hospital: Transplantation (Site #: 71107), Boston, Massachusetts, United States
🇺🇸
University of Pennsylvania Medical Center (Site #: 71111), Philadelphia, Pennsylvania, United States

Advancing Transplantation Outcomes in Children

Phase 2

Recruiting

Conditions: Kidney Transplant

Interventions: Drug: Sirolimus
Drug: Mycophenolate Mofetil
Biological: Belatacept
Drug: Tacrolimus (Group 2)
Drug: Tacrolimus (Group1)
Drug: Anti-Thymocyte Globulin (ATG)

First Posted Date: 2023-09-28

Last Posted Date: 2025-02-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 200

Registration Number: NCT06055608

Locations: 🇺🇸
University of Alabama at Birmingham (Site # 71038), Birmingham, Alabama, United States
🇺🇸
Children's Hospital of Los Angeles (Site #: 71036), Los Angeles, California, United States
🇺🇸
Cedars-Sinai Medical Center (Site #: 71026), Los Angeles, California, United States

and more 18 locations

Tocilizumab in Lung Transplantation

Phase 2

Recruiting

Conditions: Lung Transplant

Interventions: Drug: Placebo for Tocilizumab
Drug: Tocilizumab

First Posted Date: 2023-09-13

Last Posted Date: 2025-03-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 350

Registration Number: NCT06033196

Locations: 🇺🇸
St. Joseph's Hospital and Medical Center (Site #: 71192), Phoenix, Arizona, United States
🇺🇸
Cedars Sinai Medical Center (Site #: 71146), Los Angeles, California, United States
🇺🇸
David Geffen School of Medicine at UCLA (Site #: 71123), Los Angeles, California, United States

and more 12 locations

A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV

Phase 1

Active, not recruiting

Conditions: HIV

Interventions: Biological: N332-GT5 gp140 (IM, Bolus)
Biological: N332-GT5 gp140 (SC, Bolus)
Biological: N332-GT5 gp140 (IM, Fractioned)
Biological: N332-GT5 gp140 (SC, Fractioned)
Biological: SMNP (IM, Bolus)
Biological: SMNP (SC, Bolus)
Biological: SMNP (IM, Fractioned)
Biological: SMNP (SC, Fractioned)

First Posted Date: 2023-09-13

Last Posted Date: 2025-03-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 57

Registration Number: NCT06033209

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
Penn Prevention CRS [Site ID: 30310], Philadelphia, Pennsylvania, United States
🇺🇸
Bridge HIV CRS, San Francisco, California, United States

and more 5 locations

Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults

Phase 1

Active, not recruiting

Conditions: SARS-CoV-2 Infection

Interventions: Biological: B/HPIV3/S-6P

First Posted Date: 2023-09-07

Last Posted Date: 2025-03-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 27

Registration Number: NCT06026514

Locations: 🇺🇸
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy